Technical Success, Midterm Primary Patency, and Factors Affecting Primary Patency of Subintimal Angioplasty Followed by Vasculomimetic Stenting for Trans-Atlantic Intersociety Consensus II C and D Femoropopliteal Arterial Disease—A Prospective Study

 

 Permissions and Reprints

Abstract

Background The best option among the endovascular options in long, complex femoropopliteal (FP) lesions, and factors affecting the patency have yet to be well described. There are few studies describing the mid- and long-term patency of endovascular stents in long-segment FP occlusions.

Aim This study aimed to determine the technical success and mid-term patency of subintimal angioplasty with vasculomimetic stenting in Trans-Atlantic Inter-Society Consensus II (TASC) C and D FP disease. The patient and imaging factors that affect primary patency were also analyzed.

Methods and Materials A single-center prospective study was performed on 52 consecutive patients undergoing endovascular treatment for TASC C and D FP disease from 2017 to 2021. Angioplasty with stenting was performed in all patients and followed up for 36 months. Endpoints were primary patency rates and amputation-free survival of the limb. Kaplan–Meier curves were used to see patency rates and amputation-free survival rates.

Results A total of 52 patients underwent stenting with a technical success rate of 100% if the sub-intimal arterial flossing with antegrade-retrograde intervention (SAFARI) technique was used. Primary stent patency at 6, 12, 18, 24, and 36 months was 89.8, 81.4, 76.2, 71.4, and 62.5%, respectively. Amputation-free survival was 98, 95.6, 91.8, and 85.7% at 12, 24, 30, and 36 months, respectively. Cox proportional regression analysis showed smoking and vessel wall calcium score more than 270 degrees as independent predictors of loss of primary patency (hazard ratio 0.35 confidence interval [CI]: 0.003–0.448) and 0.102 (CI: 0.022–0.47), respectively.

Conclusion Subintimal angioplasty with vasculomimetic stent has good midterm patency in and amputation-free survival in long-segment FP occlusions. Smoking and severe vessel wall calcification adversely affect patency.

Author Contributions

A.J. was involved in data collection, manuscript preparation, and revision. J.V. helped in concept, manuscript preparation, and final approval. A.A. contributed to manuscript preparation, revision, and final approval. S.K. was involved in manuscript writing and final approval. P.S. was involved in the revision of the manuscript.

Publication History

Article published online:
04 December 2023

© 2023. Indian Radiological Association. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

• References

• 1 Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG. TASC II Working Group. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg 2007; 45 (Suppl S): S5-S67
  CrossrefPubMedGoogle Scholar
• 2 Conte MS, Bradbury AW, Kolh P. et al; GVG Writing Group. Global vascular guidelines on the management of chronic limb-threatening ischemia. J Vasc Surg 2019; 69 (6S): 3S-125S , e40
  CrossrefPubMedGoogle Scholar
• 3 Fanelli F, Cannavale A, Gazzetti M. et al. Calcium burden assessment and impact on drug-eluting balloons in peripheral arterial disease. Cardiovasc Intervent Radiol 2014; 37 (04) 898-907
  CrossrefPubMedGoogle Scholar
• 4 Stoner MC, Calligaro KD, Chaer RA. et al; Society for Vascular Surgery. Reporting standards of the Society for Vascular Surgery for endovascular treatment of chronic lower extremity peripheral artery disease. J Vasc Surg 2016; 64 (01) e1-e21
  CrossrefPubMedGoogle Scholar
• 5 Montero-Baker M, Schmidt A, Bräunlich S. et al. Retrograde approach for complex popliteal and tibioperoneal occlusions. J Endovasc Ther 2008; 15 (05) 594-604
  CrossrefPubMedGoogle Scholar
• 6 Antusevas A, Aleksynas N, Kaupas RS, Inciura D, Kinduris S. Comparison of results of subintimal angioplasty and percutaneous transluminal angioplasty in superficial femoral artery occlusions. Eur J Vasc Endovasc Surg 2008; 36 (01) 101-106
  CrossrefPubMedGoogle Scholar
• 7 Armstrong EJ, Saeed H, Alvandi B. et al. Nitinol self-expanding stents vs. balloon angioplasty for very long femoropopliteal lesions. J Endovasc Ther 2014; 21 (01) 34-43
  CrossrefPubMedGoogle Scholar
• 8 Bosiers M, Deloose K, Callaert J. et al. Results of the Protégé EverFlex 200-mm-long nitinol stent (ev3) in TASC C and D femoropopliteal lesions. J Vasc Surg 2011; 54 (04) 1042-1050
  CrossrefPubMedGoogle Scholar
• 9 Davaine J-M, Azéma L, Guyomarch B. et al. One-year clinical outcome after primary stenting for Trans-Atlantic Inter-Society Consensus (TASC) C and D femoropopliteal lesions (the STELLA “STEnting Long de L'Artère fémorale superficielle” cohort). Eur J Vasc Endovasc Surg 2012; 44 (04) 432-441
  CrossrefPubMedGoogle Scholar
• 10 Enzmann FK, Nierlich P, Aspalter M. et al. Nitinol stent versus bypass in long femoropopliteal lesions: 2-year results of a randomized controlled trial. JACC Cardiovasc Interv 2019; 12 (24) 2541-2549
  CrossrefPubMedGoogle Scholar
• 11 Brouillet J, Deloose K, Goueffic Y. et al. Primary stenting for TASC C and D femoropopliteal lesions: one-year results from a multicentric trial on 203 patients. J Cardiovasc Surg (Torino) 2018; 59 (03) 392-404
  PubMedGoogle Scholar
• 12 Elmahdy MF, Buonamici P, Trapani M. et al. Long-term primary patency rate after nitinol self-expandable stents implantation in long, totally occluded femoropopliteal (TASC II C & D) lesions. Heart Lung Circ 2017; 26 (06) 604-611
  CrossrefPubMedGoogle Scholar
• 13 Farber A, Rosenfield K, Siami FS, Strong M, Menard M. The BEST-CLI trial is nearing the finish line and promises to be worth the wait. J Vasc Surg 2019; 69 (02) 470-481.e2
  CrossrefPubMedGoogle Scholar
• 14 Lazaris AM, Salas C, Tsiamis AC. et al. Factors affecting patency of subintimal infrainguinal angioplasty in patients with critical lower limb ischemia. Eur J Vasc Endovasc Surg 2006; 32 (06) 668-674
  CrossrefPubMedGoogle Scholar
• 15 Clark TW, Groffsky JL, Soulen MC. Predictors of long-term patency after femoropopliteal angioplasty: results from the STAR registry. J Vasc Interv Radiol 2001; 12 (08) 923-933
  CrossrefPubMedGoogle Scholar
• 16 Willigendael EM, Teijink JAW, Bartelink M-L, Peters RJG, Büller HR, Prins MH. Smoking and the patency of lower extremity bypass grafts: a meta-analysis. J Vasc Surg 2005; 42 (01) 67-74
  CrossrefPubMedGoogle Scholar
• 17 Walsh DB, Powell RJ, Stukel TA, Henderson EL, Cronenwett JL. Superficial femoral artery stenoses: characteristics of progressing lesions. J Vasc Surg 1997; 25 (03) 512-521
  CrossrefPubMedGoogle Scholar
• 18 Davies MG, Saad WE, Peden EK, Mohiuddin IT, Naoum JJ, Lumsden AB. Impact of runoff on superficial femoral artery endoluminal interventions for rest pain and tissue loss. J Vasc Surg 2008; 48 (03) 619-625 ; discussion 625-626
  CrossrefPubMedGoogle Scholar
• 19 Lee JJ, Katz SG. The number of patent tibial vessels does not influence primary patency after nitinol stenting of the femoral and popliteal arteries. J Vasc Surg 2012; 55 (04) 994-1000 , discussion 1000
  CrossrefPubMedGoogle Scholar